US2013102579A1PendingUtilityA1

Steroids Having Increased Water Solubility and Resistance Against Metabolism and Methods For Their Production

56
Assignee: UMECRINE ABPriority: Nov 21, 2006Filed: Dec 17, 2012Published: Apr 25, 2013
Est. expiryNov 21, 2026(~0.4 yrs left)· nominal 20-yr term from priority
Inventors:Torbjörn BäckströmGianna Ragagnin
A61P 5/00A61P 37/08A61P 43/00A61P 5/24A61P 25/14A61P 25/00A61P 3/04A61P 27/02A61P 25/26A61P 25/02A61P 25/20A61P 27/16A61P 25/10A61P 25/08A61P 25/24A61P 25/22A61P 25/28A61P 3/02A61P 27/00A61P 19/08A61P 19/00A61P 15/00A61P 21/00C07J 7/00C07J 1/0011C07J 41/0016C07J 1/00C07J 7/002C07J 5/0015C07J 41/005C07J 7/009C07J 41/00C07J 7/0065C07J 7/007
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Steroid compounds having increased resistance against metabolism and increased water solubility are disclosed, together with methods for their production. These substances are suitable for the manufacture of pharmaceuticals for the treatment of steroid related or steroid induced CNS disorders and for use in methods of prevention, alleviation or treatment of such disorders.

Claims

exact text as granted — not AI-modified
1 - 8 . (canceled) 
     
     
         9 . A compound which is 3β-ethynyl, 3α-hydroxyl, androstan-17-one oxime. 
     
     
         10 - 16 . (canceled) 
     
     
         17 . A pharmaceutical composition comprising a pharmaceutically effective amount of a compound according to  claim 9  and a pharmaceutically acceptable carrier. 
     
     
         18 - 20 . (canceled) 
     
     
         21 . A method for the treatment of a CNS disorder, wherein a compound according to  claim 9  is administered to a patient in need thereof. 
     
     
         20 - 25 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.